[1] Liu B, Chen Y, Jiang LS, et al.  Is postablation whole-body 131I scintigraphy still necessary in intermediate-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL?[J]. Clin Endocrinol (Oxf), 2017, 86(1): 134-140.   doi: 10.1111/cen.13158
[2] Malamitsi JV, Koutsikos JT, Giourgouli SI, et al.  I-131 postablation SPECT/CT predicts relapse of papillary thyroid carcinoma more accurately than whole body scan[J]. In Vivo, 2019, 33(6): 2255-2263.   doi: 10.21873/invivo.11731
[3] Zhang XY, Liu LN, Chen Y, et al.  Prognostic value of post-ablation 131I scintigraphy in children with thyroid cancer[J]. Head Neck, 2020, 42(8): 1738-1745.   doi: 10.1002/hed.26088
[4] Xue YL, Qiu ZL, Song HJ, et al.  Value of 131I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature[J]. Eur J Nucl Med Mol Imaging, 2013, 40(5): 768-778.   doi: 10.1007/s00259-012-2310-x
[5] Israel O, Pellet O, Biassoni L, et al.  Two decades of SPECT/CT—the coming of age of a technology: an updated review of literature evidence[J]. Eur J Nucl Med Mol Imaging, 2019, 46(10): 1990-2012.   doi: 10.1007/s00259-019-04404-6
[6] Spanu A, Nuvoli S, Gelo I, et al.  Role of diagnostic 131I SPECT/CT in long-term follow-up of patients with papillary thyroid microcarcinoma[J]. J Nucl Med, 2018, 59(10): 1510-1515.   doi: 10.2967/jnumed.117.204636
[7]

Spanu A, Nuvoli S, Marongiu A, et al. Neck lymph node metastasis detection in patients with differentiated thyroid carcinoma (DTC) in long-term follow-up: a 131I-SPECT/CT study[J/OL]. BMC Cancer, 2020, 20(1): 239[2021-10-01]. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-06744-1. DOI: 10.1186/s12885-020-06744-1.
[8] Zilioli V, Peli A, Panarotto MB, et al.  Differentiated thyroid carcinoma: incremental diagnostic value of 131I SPECT/CT over planar whole body scan after radioiodine therapy[J]. Endocrine, 2017, 56(3): 551-559.   doi: 10.1007/s12020-016-1086-3
[9] 刘斌, 匡安仁.  重组人促甲状腺激素在分化型甲状腺癌诊治中的应用[J]. 生物医学工程学杂志, 2012, 29(3): 588-592.
Liu B, Kuang AR.  Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma[J]. J Biomed Eng, 2012, 29(3): 588-592.
[10] 刘斌, 曾宇, 王建涛, 等.  131I治疗分化型甲状腺癌肺转移吸收剂量学评价肺安全性[J]. 生物医学工程学杂志, 2010, 27(4): 852-854.
Liu B, Zeng Y, Wang JT, et al.  Lungs absorbed dose in radioiodine therapy of differentiated thyroid carcinoma with diffuse pulmonary metastases[J]. J Biomed Eng, 2010, 27(4): 852-854.
[11] 刘丽娜, 张歆玥, 刘斌, 等.  首次131I治疗前刺激性Tg对儿童及青少年分化型甲状腺癌疗效的预测价值[J]. 中华核医学与分子影像杂志, 2020, 40(6): 324-328.   doi: 10.3760/cma.j.cn321828-20200219-00054
Liu LN, Zhang XY, Liu B, et al.  Predictive value of stimulated thyroglobulin before the first 131I therapy for children and adolescents with differentiated thyroid carcinoma[J]. Chin J Nucl Med Mol Imaging, 2020, 40(6): 324-328.   doi: 10.3760/cma.j.cn321828-20200219-00054
[12]

Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual[M]. 8th ed. Switzerland: Springer, 2017.
[13] Haugen BR, Alexander EK, Bible KC, et al.  2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[14] Liu LN, Zhang XY, Tian T, et al.  Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer[J]. Thyroid, 2020, 30(7): 1017-1024.   doi: 10.1089/thy.2019.0585
[15] Tian T, Jiang LS, Zhang XY, et al.  Association between clinical and tumor features with postoperative thyroglobulin in pediatric papillary thyroid cancer[J]. Surgery, 2020, 168(6): 1095-1100.   doi: 10.1016/j.surg.2020.07.058
[16] Robinson TJ, Thomas S, Dinan MA, et al.  How many lymph nodes are enough? Assessing the adequacy of lymph node yield for papillary thyroid cancer[J]. J Clin Oncol, 2016, 34(28): 3434-3439.   doi: 10.1200/JCO.2016.67.6437
[17] Hung ML, Wu JX, Li N, et al.  Association of radioactive iodine administration after reoperation with outcomes among patients with recurrent or persistent papillary thyroid cancer[J]. JAMA Surg, 2018, 153(12): 1098-1104.   doi: 10.1001/jamasurg.2018.2659
[18] Liu B, Servaes S, Zhuang HM.  SPECT/CT MIBG imaging is crucial in the follow-up of the patients with high-risk neuroblastoma[J]. Clin Nucl Med, 2018, 43(4): 232-238.   doi: 10.1097/RLU.0000000000001984
[19] Dai HY, Huang R.  Radioiodine retention within dilated common biliary duct mimicking metastatic thyroid cancer diagnosed by the combination of SPECT/CT and MRI[J]. Clin Nucl Med, 2020, 45(10): 787-788.   doi: 10.1097/RLU.0000000000003054
[20] Liu LN, Chen Y, Tian T, et al.  Physiologic uterine uptake of radioiodine during menstruation demonstrated by SPECT/CT[J]. Clin Nucl Med, 2019, 44(12): 975-977.   doi: 10.1097/RLU.0000000000002754
[21] Liu LN, Chen Y, Tian T, et al.  An unusual false-positive uptake of radioiodine caused by metallic implants[J]. Clin Nucl Med, 2019, 44(8): e495-e496.   doi: 10.1097/RLU.0000000000002587
[22] Liu B, Tilak G, Edwards K, et al.  Intense iodine activity caused by mosquito bite[J]. Clin Nucl Med, 2013, 38(11): e414-e416.   doi: 10.1097/RLU.0b013e31827a0020
[23] Kohlfuerst S, Igerc I, Lobnig M, et al.  Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen[J]. Eur J Nucl Med Mol Imaging, 2009, 36(6): 886-893.   doi: 10.1007/s00259-008-1044-2
[24] Tian T, Chen Y, Xiang YZ, et al.  Remarkable response of pulmonary metastases rather than remnant thyroid in 131I therapy of follicular thyroid cancer[J]. Clin Nucl Med, 2019, 44(4): 327-329.   doi: 10.1097/RLU.0000000000002477